Award
NIH Reporter #11238900
Alternative Splicing and Development of Small Molecule Therapeutics in CAG Expansion Spinocerebellar Ataxias
Recipient
State University of New York at Albany
Award Amount
$570,215.00
Ceiling
$570,215.00
Awarded
December 30, 2025
Identifier
11238900
Research project awarded to State University of New York at Albany to develop small molecule therapeutics for CAG expansion spinocerebellar ataxias, focusing on alternative splicing and biomarker development, funded by NIH for $570,215.
Description
The project focuses on research related to spinocerebellar ataxias (SCAs), specifically targeting CAG expansion mutations with small molecules. The work involves identifying therapeutic compounds, studying alternative splicing dysregulation, and developing biomarkers for disease progression. The project is funded by NIH, under PA-20-185, with a total award amount of $570,215. The principal investigator is Professor and Director Andrew Berglund. The project is conducted at the State University of New York at Albany. The work aims to accelerate therapeutic development and improve understanding of CAG SCA diseases.